Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
2-(1',2'-dihydroxyethyl)-3-methylquinoxaline is a small molecule research compound developed by OMM Scientific. It is a stable chemical adduct formed by the reaction of the quorum-sensing signaling molecule Autoinducer-2 (AI-2), specifically its precursor 4,5-dihydroxy-2,3-pentanedione (DPD), with a quinoxaline-forming reagent. AI-2 is a universal signal used by both Gram-negative and Gram-positive bacteria to coordinate gene expression and biofilm formation. This compound is primarily used as a tool in preclinical research to detect, quantify, and study the AI-2 quorum sensing pathway, which is a target for developing novel antimicrobial strategies that disrupt bacterial communication rather than killing the bacteria directly.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 2-(1',2'-dihydroxyethyl)-3-methylquinoxaline.